News

Thermo Fisher Scientific vice president and general manager Verner Andersen said the acquisition of BD’s assets enables the company to provide continued availability of the product line to

Marketing head Jim Greaves said the RUO system launch is a truly transformative technology introduction, in advance of our fully regulated RenDx platform for human diagnostics that is

Istodax is indicated for treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. Celgene said that sNDA filing for Istodax

The new patent covers several new quinoxalinyl-piperazine compounds, the process for their preparation, pharmaceutical composition, and a method for their producing an anti-proliferative effect. Additionally, the new patent

Life Technologies’ new Asia Distribution Center (ADC), located in Singapore’s Tuas Biomedical Park, will provide customers with systems, consumables and services that enable researchers to accelerate scientific and

The not approvable letter was previously issued by the FDA to Jerini in 2008 for Firazyr as the treatment for acute attacks of hereditary angioedema (HAE). Firazyr is

The collaboration is expected to enhance the drug development projects and the ongoing Harvard research projects by creating a drug discovery bridge between academia and industry. Under Harvard-UCB

The FDA said Rhucin BLA was not sufficiently complete to enable a critical medical review. Additionally, it also said that thedata provided to the FDA from the previous

As part of an international collaboration reaching from Singapore to California, the scientists examined the DNA of more than 60 people with MSSE and 110 of their unaffected